brand logo

Am Fam Physician. 2015;92(7):622-623

Author disclosure: No relevant financial affiliations.

Clinical Question

Does the use of thiazide diuretics increase the risk of gout?

Evidence-Based Answer

Thiazide diuretics may be used in most patients with hypertension who have only minimally increased risk of gout. (Strength of Recommendation [SOR]: B, based on a single randomized controlled trial [RCT].) There is no increased risk in patients older than 60 years or in women, but there is a slightly increased risk (about 1%) in men younger than 60 years (SOR: B, based on a single RCT.) Usual doses of thiazides (less than 25 mg) are not associated with an increased risk of gout, although doses of 25 mg or greater are. The risk of gout with hydrochlorothiazide and chlorthalidone is similar. Thiazides may be used in patients with asymptomatic hyperuricemia because they are not associated with an increased risk of gout in these patients. (SOR: C, based on retrospective cohort studies.)

Evidence Summary

A double-blinded RCT of patients 60 years and older (n = 822) found no difference in the incidence of gouty arthritis attacks in patients who received 25 mg of hydrochlorothiazide plus 50 mg of triamterene (Dyrenium) compared with those who received placebo.1 Most of the eight patients who developed gouty arthritis were men, seven received the thiazide combination, and all had higher pretreatment uric acid levels.

A single-blinded placebo-controlled RCT (23,582 patient-years) found that treatment with bendrof luazide (a thiazide available in Europe) was associated with a slight increase in medication discontinuation due to gout in younger men, but not in women.2 Weaknesses of this study included lack of blinding for clinicians and trial evaluators, and lack of comparison of treatment groups.

A retrospective cohort study of patients 65 years and older (n = 9,249) found no associated risk of anti-gout therapy initiation in patients who received lower doses of thiazides (relative risk [RR] = 1.78; 95% confidence interval [CI], 0.66 to 4.78 for doses less than 25 mg).3 However, higher doses were associated with gout symptoms (RR = 2.39; 95% CI, 1.29 to 4.43 for doses of 25 to 49 mg; RR = 2.41; 95% CI, 1.39 to 4.19 for doses of 50 mg or more). Another retrospective cohort study (n = 3,033) found no increased risk of first-time gout attacks in patients receiving hydrochlorothiazide vs. chlorthalidone.4 A third retrospective cohort study (n = 5,234) found no associated risk of gout in patients with elevated uric acid levels who received thiazides.5

Recommendations from Others

The 2012 American College of Rheumatology guidelines for the management of gout list thiazide diuretics as a prime example of urate-elevating medications.6 The task force panel recognized the benefits of thiazides for blood pressure control and improved mortality in patients with hypertension.

Copyright Family Physicians Inquiries Network. Used with permission.

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to or email:

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Clinical Inquiries published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2015 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.